BidaskClub lowered shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) from a buy rating to a hold rating in a research note issued to investors on Tuesday morning, BidAskClub reports.

Other equities research analysts have also recently issued reports about the company. TheStreet raised Crinetics Pharmaceuticals from a d rating to a c- rating in a research note on Thursday, January 9th. ValuEngine raised Crinetics Pharmaceuticals from a hold rating to a buy rating in a research note on Friday, January 24th. Zacks Investment Research raised Crinetics Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, January 22nd. Roth Capital assumed coverage on Crinetics Pharmaceuticals in a research note on Monday, December 23rd. They issued a buy rating and a $37.00 target price for the company. Finally, HC Wainwright reissued a buy rating and issued a $35.00 target price on shares of Crinetics Pharmaceuticals in a research note on Thursday, November 21st. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $37.33.

NASDAQ CRNX opened at $22.40 on Tuesday. The stock has a fifty day moving average of $23.57 and a 200-day moving average of $19.58. The stock has a market capitalization of $539.42 million, a P/E ratio of -12.24 and a beta of 1.15. Crinetics Pharmaceuticals has a 52 week low of $14.33 and a 52 week high of $28.81. The company has a debt-to-equity ratio of 0.04, a quick ratio of 17.18 and a current ratio of 17.18.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last released its earnings results on Tuesday, November 12th. The company reported ($0.60) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.03). The firm had revenue of $0.51 million during the quarter, compared to the consensus estimate of $0.33 million. Equities research analysts forecast that Crinetics Pharmaceuticals will post -2.16 earnings per share for the current fiscal year.

In related news, Director Matthew K. Fust sold 3,500 shares of Crinetics Pharmaceuticals stock in a transaction on Monday, December 16th. The stock was sold at an average price of $22.50, for a total transaction of $78,750.00. Following the completion of the sale, the director now directly owns 16,036 shares of the company’s stock, valued at $360,810. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Vivo Capital Viii, Llc sold 7,555 shares of Crinetics Pharmaceuticals stock in a transaction on Monday, February 10th. The stock was sold at an average price of $21.40, for a total value of $161,677.00. The disclosure for this sale can be found here. Insiders sold a total of 49,740 shares of company stock valued at $1,103,429 over the last three months. Insiders own 7.40% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. Citigroup Inc. grew its stake in shares of Crinetics Pharmaceuticals by 90.1% during the fourth quarter. Citigroup Inc. now owns 2,251 shares of the company’s stock worth $56,000 after purchasing an additional 1,067 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Crinetics Pharmaceuticals by 3.4% during the fourth quarter. Bank of New York Mellon Corp now owns 35,847 shares of the company’s stock worth $899,000 after purchasing an additional 1,183 shares during the period. Bank of America Corp DE grew its stake in shares of Crinetics Pharmaceuticals by 14.9% during the fourth quarter. Bank of America Corp DE now owns 12,998 shares of the company’s stock worth $326,000 after purchasing an additional 1,690 shares during the period. Marshall Wace North America L.P. acquired a new stake in shares of Crinetics Pharmaceuticals during the first quarter worth $43,000. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Crinetics Pharmaceuticals by 3.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 52,947 shares of the company’s stock worth $1,329,000 after purchasing an additional 1,944 shares during the period. 76.92% of the stock is owned by institutional investors and hedge funds.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly.

Featured Article: How Do You Calculate Return on Equity (ROE)?

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.